Evidence map›Paper›PMID 24301058›Full record

Trial reportEuropean journal of human genetics : EJHG2014

Replication of the effect of SLC2A9 genetic variation on serum uric acid levels in American Indians.

V Saroja Voruganti, Nora Franceschini, Karin Haack, Sandra Laston, Jean W MacCluer, Jason G Umans, Anthony G Comuzzie, Kari E North, Shelley A Cole

Open access · bronzeAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in European journal of human genetics : EJHG, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2015
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Gout: a review of nonmodifiable and modifiable risk factors.Rheumatic diseases clinics of North America · 2014
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

V Saroja Voruganti1] Department of Nutrition and Nutrition Research Institute, University of North Carolina at Chapel Hill, Kannapolis, NC, USA [2] Department of Genetics, Texas Biomedical Research Institute, San Antonio, TX, USA.
Nora FranceschiniDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Karin HaackDepartment of Genetics, Texas Biomedical Research Institute, San Antonio, TX, USA.
Sandra LastonDepartment of Genetics, Texas Biomedical Research Institute, San Antonio, TX, USA.
Jean W MacCluerDepartment of Genetics, Texas Biomedical Research Institute, San Antonio, TX, USA.
Jason G Umans1] Medstar Health Research Institute, Hyattsville, MD, USA [2] Georgetown-Howard Universities Center for Clinical and Translational Science, Washington, DC, USA.
Anthony G ComuzzieDepartment of Genetics, Texas Biomedical Research Institute, San Antonio, TX, USA.
Kari E North1] Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA [2] Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Shelley A ColeDepartment of Genetics, Texas Biomedical Research Institute, San Antonio, TX, USA.
Texas Biomedical Research Institute · USUniversity of North Carolina at Chapel Hill · USMedStar Union Memorial Hospital · US

Funding

Georgetown-Howard Universities Center for Clinical and Translational Science (GHUUL1TR000101 · NCATS · GEORGETOWN UNIVERSITY · PI MELLMAN, THOMAS A, VERBALIS, JOSEPH G · 2012 to 2015
$19.3M
The Strong Heart Study, Phase VU01HL041654 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI LEE, ELISA TAN · 1988 to 2013
$19.2M
CARDIOVASCULAR DISEASE IN THE PIMA INDIANSU01HL041642 · NHLBI · MEDSTAR RESEARCH INSTITUTE · PI HOWARD, BARBARA V · 1988 to 2013
$12.6M
Epidemiology of putative genuine genetic variant: The Women's Health IntiativeU01HG004790 · NHGRI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2008 to 2012
$9.9M
Genetic Epidemiology of Causal Variants Across the Life CourseU01HG004803 · NHGRI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NORTH, KARI E. · 2008 to 2012
$9.0M
STRONG HEART FAMILY STUDYU01HL065520 · NHLBI · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI COLE, SHELLEY A · 2000 to 2011
$8.9M
Epidemiologic Architecture for Genes Linked to Environment (EAGLE)U01HG004798 · NHGRI · VANDERBILT UNIVERSITY · PI CRAWFORD, DANA C · 2008 to 2013
$8.8M
Epidemiology of Putative Causal Variants in the Multiethnic CohortU01HG004802 · NHGRI · UNIVERSITY OF HAWAII AT MANOA · PI LE MARCHAND, LOIC · 2008 to 2012
$8.4M
CARDIOVASCULAR DISEASE IN SIOUX INDIANSU01HL041652 · NHLBI · U.S. PHS INDIAN HEALTH SERVICE · PI BEST, LYLE G · 1988 to 2013
$7.9M
Quantitative Trait Locus Mapping in Human PedigreesR37MH059490 · NIMH · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI BLANGERO, JOHN · 2001 to 2010
$6.8M
NHGRI EpiGenVar Coordinating CenterU01HG004801 · NHGRI · RUTGERS, THE STATE UNIV OF N.J. · PI MATISE, TARA C. · 2008 to 2012
$4.4M
CARDIOVASCULAR EVALUATION--STRONG HEART STUDY PHASE IVU01HL065521 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI DEVEREUX, RICHARD B · 2000 to 2013
$4.3M
NCATS NIH HHS TR000101NCATS NIH HHS UL1 TR000101NCRR NIH HHS C06 RR013556NCRR NIH HHS C06 RR017515NHGRI NIH HHS U01 HG004790NHGRI NIH HHS U01HG004790NHGRI NIH HHS U01 HG004798NHGRI NIH HHS U01HG004798NHGRI NIH HHS U01 HG004801NHGRI NIH HHS U01HG004801NHGRI NIH HHS U01 HG004802NHGRI NIH HHS U01HG004802NHGRI NIH HHS U01 HG004803NHGRI NIH HHS U01HG004803NHLBI NIH HHS HL41642NHLBI NIH HHS HL41652NHLBI NIH HHS HL41654NHLBI NIH HHS HL65520NHLBI NIH HHS HL65521NHLBI NIH HHS R01 HL109301NHLBI NIH HHS U01 HL041642NHLBI NIH HHS U01 HL041652NHLBI NIH HHS U01 HL041654NHLBI NIH HHS U01 HL065520NHLBI NIH HHS U01 HL065521NIDDK NIH HHS R01 DK092238NIMH NIH HHS MH59490NIMH NIH HHS R01 MH059490NIMH NIH HHS R37 MH059490
6 · The paper itself

Abstract

Increased serum uric acid (SUA) or hyperuricemia, a risk factor for gout, renal and cardiovascular diseases, is caused by either increased production or decreased excretion of uric acid or a mix of both. The solute carrier protein 2 family, member 9 (SLC2A9) gene encodes a transporter that mediates urate flux across the renal proximal tubule. Genome-wide association studies have consistently shown the association of single-nucleotide polymorphisms in this gene with SUA in majority populations. American Indian participants of the Strong Heart Family Study, belonging to multigenerational families, have high prevalence of hyperuricemia. We conducted measured genotype analyses, based on variance components decomposition method and accounting for family relationships, to assess whether the association between SUA and SLC2A9 gene polymorphisms generalized to American Indians (n=3604) of this study. Seven polymorphisms were selected for genotyping based on their association with SUA levels in other populations. A strong association was found between SLC2A9 gene polymorphisms and SUA in all centers combined (P-values: 1.3 × 10(-31)-5.1 × 10(-23)) and also when stratified by recruitment center; P-values: 1.2 × 10(-14)-1.0 × 10(-5). These polymorphisms were also associated with the estimated glomerular filtration rate and serum creatinine but not albumin-creatinine ratio. In summary, the association of polymorphisms in the uric acid transporter gene with SUA levels extends to a new population of American Indians.

Indexed as

Genetic Predisposition to DiseaseGenome-Wide Association StudyHyperuricemiaPolymorphism, GeneticAdultFemaleGenotypeGlomerular Filtration RateGlucose Transport Proteins, FacilitativeHumansIndians, North AmericanMaleMiddle AgedUric AcidGlucose Transport Proteins, FacilitativeSLC2A9 protein, humanUric Acid

Identifiers

PMID24301058
PMCPMC4060115
OpenAlexW1975906479

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.